Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
Fiche publication
Date publication
septembre 2018
Journal
Atherosclerosis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel, Pr VERGES Bruno
Tous les auteurs :
Wargny M, Ducluzeau PH, Petit JM, Le May C, Smati S, Arnaud L, Pichelin M, Bouillet B, Lannes A, Blanchet O, Lefebvre P, Francque S, Van Gaal L, Staels B, Vergès B, Boursier J, Cariou B
Lien Pubmed
Résumé
Some studies suggested that proprotein convertase subtilisin kexin type 9 (PCSK9) is linked to liver steatosis severity and non-alcoholic steatohepatitis (NASH). We aimed to assess whether circulating PCSK9 levels are associated with either liver fat content (LFC) or histological markers of NASH in high-risk patients.
Mots clés
LDL-cholesterol, Liver biopsy, Liver fibrosis, Liver steatosis, MRI, PCSK9
Référence
Atherosclerosis. 2018 Sep 13;278:82-90